

1. Name: Renee D. Read, Ph.D.

2. Office Address: Department of Pharmacology and Chemical Biology
Emory University School of Medicine
1510 Clifton Rd NE, Suite 5017
Atlanta, GA 30322
Office telephone: 404-727-5985
Cell phone: 404-416-9759

3. Email Addresses: renee.read@emory.edu, rsdread@gmail.com

4. Current Titles and Affiliations:

a. Academic Appointments:

- i. Primary Appointment:
Associate Professor, Department of Pharmacology and Chemical Biology, Emory University School of Medicine, September 2021 - current
- ii. Joint and Secondary Appointment:
Associate Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, January 2013 - current

c. Other Academic and Administrative Appointments:

1. Cell and Molecular Biology Program Member (previously Cancer Cell Biology Program), Winship Cancer Institute, 2012 - current
2. Training Faculty, Molecular Systems Pharmacology Graduate Program, Laney Graduate School, Emory University 2012 - 2014, 2020 - current
3. Training Faculty, Biochemistry, Cell, and Developmental Biology Graduate Program, Laney Graduate School, Emory University 2012 - 2020
4. Training Faculty, Cancer Biology Graduate Program, Laney Graduate School, Emory University 2014 - 2020
5. Mentor, Discovery Phase independent research program for medical students, School of Medicine, Emory University, 2020 - current

5. Previous Academic and Professional Appointments:

- 1994 - 1996 Research Technologist, Eppley Institute for Research in Cancer, University of Nebraska Medical Center, Omaha, NE, with Dr. Thomas E. Smithgall, July 1994 - July 1996
- 2012 - 2021 Assistant Professor, Department of Pharmacology and Chemical Biology, Emory University School of Medicine, January 2012 - August 2021
- 2012 - 2021 Assistant Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, January 2013 - August 2021

9. Education:

- 1990 - 1994 B.A., Biology, *Magna cum laude*, Carleton College, Northfield, MN
- 1996 - 2003 Ph.D., Developmental Biology, Washington University, St. Louis, MO, thesis advisor Dr. Ross Cagan
- 2019 - current Teacher Certification, Community Resiliency Model, Trauma Resource Institute, CA
- 2020 - current M.P.H. expected 2023, Executive M.P.H. Program, Rollins School of Public Health, Emory University, Atlanta, GA

10. Postgraduate Training:

- 2004 - 2009 Research Associate (postdoctoral fellowship), The Salk Institute for Biological Studies, San Diego, CA, postdoctoral advisor Dr. John B. Thomas
- 2009 - 2011 Senior Research Associate (postdoctoral fellowship), The Salk Institute for Biological Studies, San Diego, CA, postdoctoral advisor Dr. John B. Thomas; Ludwig Institute for Cancer Research, University of California – San Diego, San Diego, CA, postdoctoral co-mentors Drs. Webster Cavenee and Frank Furnari

11. Continuing Profession Development Activities:

1. Junior Faculty Development Course, Emory University School of Medicine. This semester-long 11 session course is specifically for junior faculty in the School of Medicine. The course promotes self-awareness, and teaches junior faculty SOM policies and best practices in ethics, human resources, finances, and promotion. The course also includes sessions on teaching skills, conflict negotiation skills, grant and manuscript writing, and leadership development. (34 hours) 2014
2. Atlanta Society of Mentors (ASOM), Mentorship Training Class. Emory University. This 6 session class provides mentors with tools to become better communicators through improved self-awareness and effective “crucial conversations” with trainees and peers. Major ASOM goals are to improve the mentoring culture, to nurture talent from under-represented groups, and to provide trainees with support to pursue careers of their choice. (10 hours) 2017
3. Peer Reviewer, Mock Study Section, American Brain Tumor Association Alumni Research Network (AARN). This served to educate and coach AARN members in best practices in grant writing and reviewing. AARN members submitted grants for NIH study-section style reviews, and 3 other AARN reviewers and I reviewed and openly discussed proposals with each other, with grant writers, and with the larger AARN membership, with the goal of improving funding outcomes for AARN members. (6 hours total). 2017
4. Birkman Method Assessment and Workshop. Emory University. The Birkman Method is an evidence-based personality, social perception, and occupational interests assessment designed to provide insight to greater self-awareness and self-responsibility. Assessments measure external social behaviors, internalized expectations of interpersonal interactions, and potential stress reactions to unmet expectations. Workshop strives to improve interpersonal awareness and effectiveness in order to promote success. (5 hours) 2018
5. Unconscious Bias Training. Emory University. This workshop was designed to educate and inform faculty of the nature and consequences of unconscious bias in academic medicine and research science, and sought to implement strategies designed to limit the impact of unconscious bias on faculty and staff hiring practices at Emory. The training included IAT (<https://implicit.harvard.edu/implicit/selectatest.html>) assessments to make individual faculty aware some of their specific biases. (1.5 hours) 2018
6. Learning to be Better Teachers Conference and Workshops, Emory University School of Medicine. A full-day Emory workshop, which provide faculty with opportunities to enhance their teaching skills through interactions with colleagues across the School of Medicine. I attended workshops on topics including: a) inclusive teaching, b) growth mindset, c) root cause analysis, d) trauma informed care, e) art in education, f) feedback as coaching, g) writing recommendations, and h) mentoring strategies. (8 hours/year) 2018, 2019, 2020
7. Community Resiliency Model (CRM) Teacher Training and Certification, Trauma Resource Institute and Emory University. 6 all-day didactic and experiential training sessions, and 7 continuing education webinars. CRM is an evidence-based mindfulness intervention that

adapts insights from trauma-informed care and interpersonal neuroscience. CRM skills are based on “bottom-up” sensory awareness rooted in well-established somatic and motor psychotherapies. In CRM teacher training, participants learn the biology of human reactions to stress and trauma, skills to track and intensify sensations connected to well-being and resilience, and to teach these sensory mindfulness skills to others. CRM skills increase the ability to return from a dysregulated emotional state to a balanced state when overwhelmed. I am now part of a national network of certified CRM teachers. (50 hours) 2019

8. Cognitively Based Compassion Training (CBCT) for Health Professionals, SOM Faculty-Staff Course, Emory University School of Medicine. Emory’s CBCT is a sequenced cognitively-based compassion training program that provides practices to strengthen the capacity to care for others while decreasing negative effects of empathic distress by improving attentional stability and sustaining a spontaneous compassionate responsiveness. (10 hours) 2019
9. “Handling Difficult People in the Workplace,” Research Survival Skills Seminar Series, Emory University School of Medicine. The provided practical training for addressing challenging professional relationships and interpersonal conflict in the workplace. (1 hour) 2019
10. “Supporting Yourself and Your Trainees During the Coronavirus Pandemic,” Webinar and Online Discussion, Office of Intramural Training and Education, National Institutes of Health. This workshop provided PIs, program leaders, and research heads with insights and strategies for supporting researchers during the pandemic. (2 hours) 2020
11. “Moving from Bystander to Upstander,” Webinar and Online Discussion Office of Intramural Training and Education. National Institutes of Health. This training program was designed to empower members of the research community to speak up and intervene when they witness bullying, incivility, microaggressions, and hate speech, with a focus on issues experienced in research groups and hate speech related to the coronavirus pandemic. (2 hours) 2020
12. “Building Awareness: Diversity, Equity, and Inclusion,” School of Medicine Office of Faculty Academic Advancement, Leadership & Inclusion, Department of Pharmacology and Chemical Biology. This seminar was to aid our ability to foster a welcoming and inclusive environment in the department for enhanced success and global impact. (1 hour) 2020
13. “Clinical Trials Course,” Society for Neuro-Oncology, Virtual. This 2-day course offered didactic lectures presented by faculty and regulatory personnel with specific areas of expertise with respect to practical aspects of therapeutic CNS clinical trials, including: Fundamentals of good trial design; understanding scientific, statistical, regulatory, logistical and ethical aspects; integrating correlative studies; mitigating challenges to accrual and overcoming accrual barriers; and anticipating future direction of CNS trials. (8 hours) 2020

13. Committee Membership:

a. National and International:

1. Leadership Committee, Member, American Brain Tumor Association Alumni Research Network (AARN), 2012 - 2015
* duties: This committee set AARN membership priorities and recommended yearly conference career development activities and research seminar topics.

c. Institutional

1. Faculty Search Committee Member, Department of Pharmacology, 2016
2. Postdoctoral Advisory Committee, Emory University, 2016 - 2019
* duties: This committee met monthly-quarterly to review the status of research training, salary and benefits, and career development opportunities for

- postdoctoral fellows, and the committee made recommendations and set policies designed to improve training and professional development opportunities for postdoctoral fellows.
3. Cancer Animal Models Core Advisory Committee, Winship Cancer Institute, 2016 - current
 4. Chair of the Curriculum Committee, Cancer Biology Graduate Program, 2017 - 2019
* duties: I worked with the Cancer Biology Executive Committee, Cancer Biology Curriculum Committee, and the curriculum chairs of other GDBBS programs to redesign the Cancer Biology curriculum for first year students in order to improve their research performance and recommended redesign of IBS 524 Advanced Cancer Biology
 5. Executive Council, Cancer Biology Graduate Program, 2017 - 2019
 6. Rotations Committee, Biochemistry, Cell, and Developmental Biology Graduate Program, 2017 - 2020
 7. Faculty Search Committee Member, Department of Pharmacology, 2018
 8. Graduate Division of Biology and Biomedical Sciences Career Development Team, Cancer Biology Graduate Program Representative, 2018
 9. Translational and Clinical Research Stakeholder Team, Emory University School of Medicine, 2018
 10. Integrated Cellular Imaging Core Faculty Advisory Committee, Major User Group, Emory Integrated Core Facilities, 2018 - current
 11. IACUC Advisory Committee, Winship Cancer Institute Representative, 2019 - 2020
* duties: I served as a faculty representative and consultant in an intensive administrative and research review of current IACUC and DAR practices. I contributed to a set of comprehensive recommendations for changes in IACUC and DAR services and practices designed to improve support of animal research and ensure regulatory compliance.
 12. Departmental re-opening committee, Department of Pharmacology and Chemical Biology, 2020
 13. Women in Science at Emory (WiSE), member, 2020 - current
 14. Women in Winship Committee, member, Winship Cancer Institute, 2020 - current
 15. Elkin Lecture Committee, member, Winship Cancer Institute, 2020 - 2022
* duties: I review and recommend speakers for weekly Winship seminar series, ensuring that a comprehensive and diverse range of scientific and educational topics and speakers are featured in this pre-eminent seminar series.
 16. Scientific Advisory Board, member, Office of Community Outreach and Engagement, Winship Cancer Institute, 2020 - current
* duties: The goal of this committee is to develop community partnerships in the Winship catchment and to engage with Winship researchers and clinicians in developing research studies and deliver programs that address cancer disparities.
 17. Community Outreach and Engagement Liaison, Cell and Molecular Biology Program, Community Outreach and Engagement Program, Winship Cancer Institute, 2022 – current

14. Peer Review Activities:

a. Grants:

i. National and International:

1. NIH-CSR, Tumor Cell Biology Study Section (TCB), ad hoc reviewer, October 2013, February 2017
2. Rally Foundation for Childhood Cancer Research, peer reviewer for consortia grants,

- individual investigator grants, and postdoctoral fellowship grants, fall and summer 2017, 2018, 2019, 2020 grant cycles
3. Johnson Cancer Research Center, Kansas State University, external reviewer, Innovative Research Award program, November 2018
 4. Natural Sciences and Engineering Research Council of Canada, ad hoc reviewer, Discovery Grants Program, January 2019
 5. American Brain Tumor Association, Discovery Grant Peer Review Committee, May 2019
 6. NIH-CSR, Synapses, Cytoskeleton and Trafficking Study Section (SYN), ad hoc reviewer, May 2019
 7. NIH-CSR, Cancer Biotherapeutics Development Special Emphasis Study Section (CBD), ad hoc reviewer, November 2019
 8. Medical Research Council (MRC), Molecular and Cellular Medicine Board, Cancer Section, United Kingdom (U.K.), ad hoc reviewer, June 2020
 9. American Brain Tumor Association, Discovery Grant Peer Review Committee, 2020 – 2021
 10. NIH-CSR, Oncological Sciences Fellowship Study Section (F09B), ad hoc reviewer, November 2021
 11. American Brain Tumor Association, Fellowship Peer Review Committee, 2021 – current
 12. NIH-CSR, Cancer Therapeutics and Drug Development Special Emphasis Study Section (ZRG OTC-M 80), ad hoc reviewer, February 2021
 13. American Brain Tumor Association, Fellowship Peer Review Committee, 2021 – 2022
 14. NIH-CSR, Developmental Therapeutics (DT) Study Section, ad hoc reviewer, June 2022

iii. Institutional:

1. Pilot Grant Review Committee, Winship Invests Pilot Project Program, Winship Cancer Institute, December 2015
2. Pilot Grant Review Committee, Aflac Cancer and Blood Disorders Center, June 2017, August 2018, September 2021
3. Catalyst Grant Review Committee, Department of Pharmacology, July 2018
4. Winship Invests/Lung Cancer SPORE Pilot Proposal Developmental Research Program Grant Review Committee, Winship Cancer Institute, June 2020
5. Donaldson Charitable Trust Review Committee, Aflac Cancer and Blood Disorders Center, Winship Cancer Institute, December 2021

b. Manuscripts:

1. *Laboratory Investigation* (2009)
2. *Neuron Glia Biology* (2010)
3. *Science Signaling* (2011)
4. *Journal of Neuro-Oncology* (2010)
5. *PLoS One* (2011, 2014)
6. *Molecular Pharmacology* (2015)
7. *PLoS Biology* (2015)
8. *eLife* (2016 - current)
9. *Cancer Research* (2018 - current)
10. *Nature Communications* (2018 - current)
11. *Neuro-Oncology* (2018 - current)
12. *Communications Biology* (2020 - current)
13. *Development* (2020 - current)

14. *PloS Genetics* (2021 - current)

c. Conference Abstracts:

1. Abstract Reviewer, *Drosophila* Models of Human Disease, 56th Annual *Drosophila* Research Conference, Chicago, IL. March 2015
2. Abstract Reviewer, Cell Signaling/Genetics/Epigenetics, Annual Scientific Meeting of the Society for Neuro-Oncology, Scottsdale, AZ. November 2017
3. Abstract Reviewer, 24th Neuro-Tumor Club Meeting, in association with The Society for Neuro-Oncology and the AACR Annual Meeting, Atlanta, GA. April 2019
4. Abstract Reviewer, Using *Drosophila* for Investigations of Glia Based Human Diseases, XIV European Meeting on Glial Cell Function in Health and Disease, Porto, Portugal. July 2019

d. External Thesis Review Committees:

i. National and International:

1. Dissertation Review Committee, Ioannis Kaffes, Medicine, Charité - Universitätsklinikum Berlin, Germany, 2021.
2. Thesis Review Committee Member, Walt Krueger, Neuroscience Graduate Program, The University of Tennessee Health Science Center, Neuroscience Institute, laboratory of Dr. Lawrence Reiter, 2022 - current
3. Thesis Review Committee Member, Marco Gualtieri, Sorbonne University, laboratory at Pauline Spéder at the Institut Pasteur, Paris, France, 2022- current

15. Consultants/Advisory Boards:

1. Medical Advisory Board, Rally Foundation for Childhood Cancer Research, 2016 - current
* duties: I serve as a scientific advisor to the foundation leadership regarding pediatric brain tumor basic and translational research priorities.

17. Honors and Awards:

1. Sigma Xi, 1994
2. NIH Training Grant, Developmental Biology, Washington University School of Medicine, 1996
3. Honorable Mention, NSF Graduate Research Fellowship Competition, 1997
4. Travel Scholarship, Keystone Symposium on Specificity in Signal Transduction, 1999
5. Victor Hamburger Award, for excellence in developmental biology, Washington University, 2002
6. Jakschik Award, in recognition of research excellence at Washington University, 2003
7. National Research Service Award, National Institute of Neurological Disorders and Stroke, 2005
8. Novel and Newsworthy Abstract, 46th Annual Meeting, American Society for Cell Biology, 2006
9. American Brain Tumor Association Postdoctoral Fellowship Award, 2008
10. K99/R00 Pathway to Independence Award, National Institute of Neurological Disorders and (NINDS), National Institutes of Health (NIH), 2009
11. Southeastern Brain Tumor Foundation, Phil Jory Award, 2013
12. Discovery Award, American Brain Tumor Association, 2015
13. Emerging Leader Award, Ben and Catherine Ivy Foundation, for high-risk high-reward research on glioblastoma, 2020

14. Researcher Appreciation Day Recognition Award, Emory School of Medicine, 2020

18. Society Memberships:

1. Genetics Society of America (GSA), 1997 - current
2. Society for Neuro-Oncology (SNO), 2012 - current
3. American Brain Tumor Association Alumni Research Network (AARN), by invitation only from ABTA's senior scientific advisors, for select recipients of ABTA funding based on their potential impact on brain tumor research; 2012 - current
4. American Society for Pharmacology and Experimental Therapeutics (ASPET), 2019 - current

19. Organization of Conferences:

a. National and International:

i. Administrative Positions

1. Organizer and Co-chair, American Brain Tumor Association Alumni Research Network (AARN), Annual Meeting, Chicago, IL. September 2018
* duties: Interviewed and invited speakers, including NCI officials and national leaders and in the clinical neuro-oncology community to speak about clinical trials, and molecular diagnostics; organized program; moderated questions for invited speakers, and organized a new session on wellness and burn-out
2. Co-organizer, 24th Neuro-Tumor Club Meeting, in association with The Society for Neuro-Oncology and the AACR Annual Meeting, Atlanta, GA. April 2019
* duties: Invited speakers and poster presenters, organized program, invited individual participants and attendees, guidance on location and transportation

ii. Sessions as Chair and Co-Chair:

1. Platform and Poster Session Co-chair, *Drosophila* Models of Human Disease, 56th Annual *Drosophila* Research Conference, Chicago, IL. March 2015
2. eTalk Session Moderator, Cell Signaling/Genetics/Epigenetics, 22nd Annual Scientific Meeting of the Society for Neuro-Oncology, Scottsdale, AZ. November 2017
3. Session Moderator, "AARN Member Panel: Mentoring." American Brain Tumor Association Alumni Research Network (AARN), Annual Meeting, Chicago, IL. September 2018
4. Platform Session Moderator, Metabolomics/Cell Biology/Cell Signaling, 23rd Annual Scientific Meeting of the Society for Neuro-Oncology, New Orleans, LA. November 2018
5. Co-chair, Using *Drosophila* for Investigations of Glia Based Human Diseases, XIV European Meeting on Glial Cell Function in Health and Disease, Porto, Portugal. July 2019

c. Institutional:

i. Administrative positions:

1. Faculty Organizer, Yearly Retreat, Cancer Biology Graduate Program, Emory University. 2017
2. Poster Judge, 10th Postdoc Research Symposium, Emory University. 2017

ii. Sessions as Chair:

1. Session Chair, White Lab Coat Presentation for Degree Candidates, Yearly Retreat, Cancer Biology Graduate Program, Emory University. 2019

21. Community Outreach:

1. Medical Volunteer, Planned Parenthood of Nebraska and Council Bluffs (PPNCB), Omaha, NE, interviewed and counseled patients on family planning options and healthcare, performed routine medical tests, trained/supervised by staff nurses and physicians. 1994 - 1996
2. Southeastern Brain Tumor Foundation, Race for Research 5K, Atlanta, GA. Invited short lay seminar on SBTF funded brain tumor research, and fundraising run for the brain tumor community. September 2013, 2018, 2019
3. Rally Foundation for Childhood Cancer Research, Reception with Donors and key Stakeholders, Atlanta, GA. As a funded Rally Foundation researcher, I met with donors, patients, and families interested in learning about research on brain tumors. September 2016
4. "Emerging Innovators in Brain Tumor Research." Lay Invited Seminar for clinicians, patients, and caregivers. American Brain Tumor Association National Patient and Family Conference, Chicago, IL. August 2018
5. Donor Site Visit, Scientific Presentation, and Laboratory Tour. Rally Foundation for Childhood Cancer Research. Department of Pharmacology and Chemical Biology, Emory University School of Medicine, Atlanta, GA. August 2019
6. "Community Resiliency Model." Invited Training Workshop and Experiential Exercises. Georgia Department of Family and Children Services. Co-taught with Dr. Linda Grabbe from the Emory University School of Nursing. Griffin, GA. February 2020
7. Communications and Community Building Committee, Grady Cares Closet, Grady Cares parent volunteer group affiliated with Henry Grady High School, Atlanta, GA. 2020
8. "What is glioma?" I provided expert quotes for an educational blog and press release associated with Glioblastoma Awareness Day on the website of the Rally Foundation for Childhood Cancer Research. (<https://rallyfoundation.org/what-is-a-glioma/>). July 2020

22. Formal Teaching:

a. Medical Student Teaching:

1. Endocrinology and Reproductive Health, Reproductive Health Module, Reproductive Pharmacology I, Fall Semester 2015 - 2021 (1 contact hours/year). Lecturer.
2. Endocrinology and Reproductive Health, Reproductive Health Module, Reproductive Pharmacology II, Fall Semester 2015 - 2021 (2 contact hours/year). Lecturer.
3. Foundations of Medicine Prologue 2, Pharmacology Fundamentals, Small Group Problem Set, 2016, 2018, 2019 (3 contact hours/year). Discussion Leader.

b. Graduate Programs:

iii. Masters and Ph.D. Graduate Program Teaching:

1. BCBD 501 Foundations I; Module in Cell Signaling. Fall Semester 2013, 2014, 2018 (20 contact hours/year). Lecturer.
2. BCBD 502 Foundations II; Module in Stem Cell Biology. Spring Semester 2013, 2014 (20 contact hours/year). Lecturer.
3. IBS 556 Basic Biomedical and Biological Sciences; lecture on Cell Cycle and Checkpoints. Spring Semester 2014, 2015 (2 contact hours/year). Lecturer.
4. IBS 524 Advanced Cancer Biology II; lectures on Receptor Tyrosine Kinase Signaling in Cancer I and II. Spring Semester 2015, 2016, 2018, 2019 (4 contact hours/year).

- Lecturer.
5. IBS 531 Principles of Molecular and Systems Pharmacology; lectures on Protein Kinase and Phosphatases I and II. Fall Semester 2015 - 2021 (4-5 contact hours/year). Lecturer.
 6. BCDB 597R Laboratory Rotations, 2017 - 2020 (12 contact hours/year). Rotation Report Reviewer and Grader.
 7. IBS 531 Principles of Molecular and Systems Pharmacology; lectures on RNA Processing, Translation, and Protein Synthesis I and II, Fall Semester 2018 - 2021 (4-5 contact hours/year). Lecturer.
 8. MSP 717 Therapeutic Discovery; lecture on Animal Models in Drug Discovery. Spring Semester 2019, 2022 (2 contact hours/year). Lecturer.
 9. MSP 501 Ethical Issues in Pharmacology. Academic Year 2020 – 2022 (12 contact hours/year). Course Co-Director and Lecturer.

c. Other Categories:

i. Journal Clubs and Research Interest Discussion Groups:

1. Neural Tumors Interest Group. This group, led by PIs from over 6 neuro-oncology research labs met monthly for informal presentations and discussion of research projects and grant submissions, 2016 - 2019 (6 contact hours/year). Faculty Participant.
2. Neuro-Oncology Journal Club, 2018 - 2020 (8 contact hours/year). Faculty Participant.

ii. Allied Health Program Formal Teaching:

1. BAHS 504, Allied Health Program, Introduction to Pharmacology; lectures on Immunosuppressive Drugs and Anti-inflammatory Drugs, Spring Semester 2015 - 2022. (2 contact hours/year). Lecturer.

iii. Masters and Ph.D. Graduate Program Workshops:

1. Workshop on Wellness and Mental Health, Cancer Biology Career Development Workshops; graduate students, 2019 (1 contact hour/year). Organizer and Lecturer.
2. Workshop on How to Select a Postdoctoral Position, Cancer Biology Career Development Workshops; graduate students, 2019 (1 contact hour/year). Organizer and Discussion Leader.
3. Workshop on Community Resiliency Model Skills, Cancer Biology Career Development Workshops; graduate students, 2019 (2 contact hours/year). Organizer and Lecturer.

iv. Other Ph.D. Graduate Teaching:

1. Written Qualifying Exam Committee, Biochemistry, Cell, and Developmental Biology Graduate Program, 2014, 2015 (6 hours/year).
2. Written Qualifying Exam Committee, Cancer Biology Graduate Program, 2015, 2017 - 2020 (6 hours/year).
3. Oral Qualifying Exam Committee for Hye Rim Kim, Ph.D. Student, Cancer Biology Graduate Program, 2016 (4 hours).
4. Oral Qualifying Exam Committee for Max Griffin, Ph.D. Student, Cancer Biology Graduate Program, 2018 (4 hours).
5. Oral Qualifying Exam Committee for Izbela Suster, Ph.D. Student, Biochemistry, Cell, and Developmental Biology Graduate Program, 2019 (4 hours).

23. Supervisory Teaching:

a. Masters and Ph.D. Students directly supervised:

1. Alexander Chen, Ph.D. Student, Cancer Biology Program, 2015 - 2020
awards: Honorable Mention, Graduate Division of Biology and Biomedical Science, Image Competition, 2016
Postdoctoral Fellowship in T32 award in Regenerative Medicine*, 2020
**this is a highly competitive T32 award to support postdoctoral training within Washington University's Center for Regenerative Medicine*
current position: postdoctoral fellow, Dr. David Gutmann, advisor, Washington University School of Medicine, St. Louis, MO
2. Riley Gulbranson, Masters Student, Cancer Biology 4+1 Program, 2018 - 2020
current position: Public Health Associate Fellow, Centers for Disease Control
3. Julia Gonzalez, Masters Student, Cancer Biology 4+1 Program, 2021 – current
awards: Diversity Supplement, NINDS, 2022 - current *this is a competitively awarded supplement to R21NS116639-A1

b. Postdoctoral Fellows directly supervised:

1. Krishanthan Vigneswaran, M.D., Resident, co-mentored with Dr. Jeffrey Olson, Department of Neurosurgery, Emory University School of Medicine, July - October 2014, 2016 - 2018.
funding: NINDS R25 Research Education Grant supplement*, 2016 - 2018
Neurosurgery Research and Education Foundation and AANS/CNS Section on Neurological Surgery Research Fellowship Grant **, 2017 - 2018
awards: Resident Research Award for top presentation from a resident or fellow, 2017 Grady Memorial Medical Research Symposium, Atlanta, GA.
SNS Basic Science Award, 2018 Southern Neurosurgical Society Annual Meeting
**this is a highly competitive national award for physician-scientists to supplement training associated with our institutional NINDS R25 research education program in neurology and neurosurgery (Oyesiku, PI)*
***this is a highly competitive national award for scientist neurosurgeons*
current position: Assistant Professor, Department of Neurosurgery, University of Texas - Houston
2. Joanna Wardwell-Ozgo, Ph.D., Postdoctoral Fellow, FIRST program, Emory University, 2015 - 2016.
funding: T32 FIRST postdoctoral fellowship*, 2015 - 2018
awards: Genetics Society of America Travel Award**, 2016
**highly competitive inter-institutional T32 IRACDA program (Eaton, PI), applicants are selected after a yearly national application and interview process*
***highly competitive national award in support of her attendance and research presentation at the 2016 Allied Genetics Conference*
current position: Postdoctoral Fellow, advisor Dr. Kenneth Moberg, Department of Cell Biology, Emory University
3. Se-Yeong Oh, Ph.D., Postdoctoral Fellow, Emory University, 2016 - 2022
funding: Postdoctoral Fellowship, Rally Foundation for Childhood Cancer Research*, 2018 - 2020
awards: Korea America Society in Biotech and Pharmaceuticals, KASBP-KHIDI Fellowship,** 2022
**this is a highly competitive national fellowship award program for Ph.D. and/or M.D. scientists who focuses on translational pediatric cancer research*
***this is a highly competitive national fellowship award program for Ph.D. and/*

or M.D. Korean and Korean-American scientists working in the U.S.
current position: Senior Scientist, ProFound Therapeutics, Boston, MA, 2022 - current

4. Nathaniel Boyd, Ph.D., Postdoctoral Fellow, Emory University, 2018 - 2020
funding: T32 postdoctoral fellowship in Translational Neurology*, 2018 - 2020
awards: Scholar-in-Training award for the 2020 AACR Annual Meeting,** 2020
American Association for Advancement of Science (AAAS) Science
and Technology Fellowship***, 2020 - current
**this is competitively awarded support on the T32 training grant in translational
neurology associated with the Center for Neurodegeneration (Levey, PI)*
*** this is an internationally competitive travel scholarship*
****this is a highly competitive national fellowship award program for Ph.D., M.D.
scientists who want to transition to a career in science policy at the federal level*
current position: American Association for Advancement of Science (AAAS), Science
and Technology Fellow, Department of Defense, Congressionally Directed Medical
Research Programs, United States federal government, 2020 - current

d. Thesis Committees:

1. Daniel Barron, Biochemistry, Cell, and Developmental Biology Program, Emory University, 2014 - 2016
current position: psychiatry resident at University of Pennsylvania
2. Phil Byun, Genetics and Molecular Biology Program, Emory University, 2014 - 2019
current position: Ph.D. Intern at AKESOgen, Inc.
3. Hope Robinson, Cancer Biology program, Emory University, 2016 - 2019,
current position: postdoctoral fellow with Dr. Kavita Dhodapkar, Emory University
4. Hye Rim Kim, Cancer Biology program, Emory University, 2016 - 2019,
current position: Senior Researcher, Genome and Company, Korea
5. James Ross, Cancer Biology Program, Emory University, 2017 - 2019,
current position: postdoctoral fellow with Dr. Rafi Ahmed, Emory University
6. Briana Rackley, Cancer Biology Program, Emory University, 2017 - 2020
7. Samantha Lanjewar, Genetics and Molecular Biology Program, Emory University, 2020 -
current
8. Caitlin Sojka, Neuroscience Program, Emory University, 2020 – current

e. Other:

i. Medical Students and Residents Independent Research directly supervised:

1. Andrew Boucher, M.D., Resident, co-mentored with Dr. Jeffrey Olson, Department of Neurosurgery, Emory University School of Medicine, July - November 2018
current position: Neuro-Oncology Neurosurgery Fellowship, Emory University
2. Brian Mott, 4th year Medical Student, Discovery Phase independent research
Emory University School of Medicine, November 2020 – August 2021

ii. Undergraduate Independent Research Students directly supervised:

1. Arome Obende, Undergraduate Research Advisee, Independent Study, Biology 499,
Department of Biology, Emory University, 2014 - 2015
current position: M.D. student at Tufts University
2. Nilang Shah, Undergraduate Research Advisee, Independent Study, Biology 499, 2015 -
2016, and SURE Undergraduate Research program, Emory University, summer 2016

awards: Victoria Finnerty Travel Award*, 2016

**highly competitive national award in support of his attendance and research presentation at the 2016 Allied Genetics Conference*

current position: M.D./Ph.D. student at University of California – Davis

3. Corey Sylber, Undergraduate Research Advisee, Department of Pharmacology, Emory University, 2015 - 2016
current position: research specialist at Emory University School of Medicine
4. Deidre Wright, Undergraduate Research Advisee, Independent Study, Biology 499, Department of Biology, Emory University, 2016 - 2017
current position: M.D. student at Medical College of Georgia
5. Emma Marin Miller Undergraduate Research Advisee, Department of Pharmacology, Emory University, 2017 - 2019
current position: M.D. student at The Medical University of South Carolina
6. Jerry William Allen, Honors Biology Thesis Advisee, Department of Biology, Emory University, 2018 - 2019
awards: High Honors in Biology, 2020
current position: research specialist at Brigham and Women's Hospital
7. Ashleigh Acker, Undergraduate Research Advisee, Independent Study, Biology 499, Department of Biology, Emory University, 2019 - 2020
current position: Masters in Biotechnology student, Northwestern University

iii. Graduate Students, rotations and other significant mentoring activities:

1. Lindsey Knapp, Ph.D. Student, Biochemistry, Cell, and Developmental Biology Program, Emory University, rotation, rotation report, 2013
2. Briana Brown (Rackley), Ph.D. Student, Cancer Biology Program, Emory University, rotation, rotation presentation, 2014
3. Emily Legan, Ph.D. Student, Biochemistry, Cell, and Developmental Biology Program, Emory University, rotation, rotation report, 2017
4. Jamie Hamilton, Ph.D. Student, Cancer Biology Program, Emory University, rotation, rotation presentation, qualifying exam preparation and mentoring, 2017
5. Leon McSwain, Ph.D. Student, Cancer Biology Program, Emory University, rotation and short-term thesis mentor, 2018 – 2019
6. Benjamin Babcock, Ph.D. Student, Cancer Biology Program, Emory University, rotation, rotation presentation, 2019
7. Sarah Shapley, Ph.D. Student, Neuroscience Program, Emory University, rotation, rotation presentation, 2021
8. Camille Trautman, Ph.D. Student, Neuroscience Program, Emory University, rotation, rotation presentation, 2022
9. Emmie Banks, Ph.D. Student, Neuroscience Program, Emory University, rotation, rotation presentation, 2022

iv. Post-Baccalaureate, directly supervised:

1. Mitchell Buck, B.S., gap year/research specialist, 2012
current position: Engineer at Thermo Fisher Scientific
2. Clay Coston Rowe, B.S., gap year/research specialist, 2013 – 2015
current position: D.O. student at the Philadelphia College of Osteopathic Medicine
3. Shoeb Lallani, B.S., gap year/research specialist, 2017 – 2018
awards: Georgia Neurosurgical Society, Spring Meeting Paper Award for top scoring presentation from a trainee, resident or fellow, 2018

American Brain Tumor Association Student Fellowship, 2019
current position: Neurology Residency at Stanford University School of Medicine
4. Elizabeth Young, gap year/research specialist, 2020 -current

v. Postdoctoral Advisory Committees:

1. Katie Williamson, M.D., Hematology/Oncology Fellow, Department of Pediatrics, Emory University School of Medicine, Scholar Oversight Committee Chair, 2014 – 2016
2. Shubin Shahab, M.D., Ph.D., Pediatric Neuro-Oncology Fellow, Department of Pediatrics, Emory University School of Medicine, Scholar Oversight Committee member, 2019 – current

24. Lectureships, Seminar Invitations, and Oral Presentations:

a. National and International:

1. “Modeling human brain cancer in fruit flies.” Department of Embryology, Carnegie Institution of Washington, Baltimore, MD. (Invited Seminar). July 2006
2. “Modeling glioma in *Drosophila*.” Ludwig Institute for Cancer Research, New York Branch New York, NY. (Invited Seminar). July 2006
3. “Modeling Human Brain Cancer in *Drosophila*.” Sanford Burnham Cancer Center, Sanford Burnham Institute, San Diego, CA. (Invited Seminar). March 2007
4. “Modeling Human Brain Cancer in Fruit Flies.” Stanford Institute for Stem Cell Biology and the Stanford Cancer Center, Stanford University School of Medicine, Stanford, CA. (Invited Seminar). August 2007
5. “Manipulating *Drosophila* Glia to Model Human Glioma.” Division of Experimental Hematology & Cancer Biology, Cincinnati Children’s Hospital, Cincinnati, OH. (Invited Seminar). January 2010
6. “Manipulating *Drosophila* Glia to Model Human Glioma.” Life Sciences Institute, University of Michigan, Ann Arbor, MI. (Invited Seminar). January 2010
7. “Manipulating *Drosophila* Glia to Model Human Glioma.” Institute of Neuroscience, University of Oregon, Eugene, OR. (Invited Seminar). February 2010
8. “Manipulating *Drosophila* Glia to Model Human Glioma.” Department of Genetics, MD Anderson Cancer Center, Houston, TX. May 2010
9. “Manipulating the kinome in *Drosophila* Glia to Model Human Glioma.” MD Anderson Brain Tumor Center, MD Anderson Cancer Center, Houston, TX. (Invited Seminar). July 2010
10. “Manipulating *Drosophila* Glia to Model Human Brain Cancer.” Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California – Los Angeles, Los Angeles, CA. (Invited Seminar). December 2010
11. “Manipulating *Drosophila* Glia to Model Human Glioma.” Department of Biochemistry and Cell Biology, University of New York, Stony Brook, NY. (Invited Seminar). February 2011
12. “Manipulating the Kinome in *Drosophila* Glia to Model Human Glioma.” Huntsman Cancer Institute, University of Utah, Salk Lake City, UT. (Invited Seminar). February 2011
13. “Manipulating the Kinome in *Drosophila* Glia to Model Human Glioma.” Department of Microbiology and Molecular Genetics, University of Pittsburgh, Pittsburgh, PA. (Invited Seminar). March 2011

14. "Manipulating the Kinome in *Drosophila* Glia to Model Human Glioma." Moores Cancer Center, University of California – San Diego, CA. (Invited Seminar). April 2011
15. "Receptor Tyrosine Kinase Signaling Pathways in post-embryonic neurogenesis and pediatric brain tumors: from fruit fly models to drug targets for human clinical trials." Neuroscience Program Seminar Series, University of Colorado School of Medicine, Denver, CO. (Invited Seminar). October 2016
16. "A multidisciplinary approach to drug target discovery for brain tumors." Ludwig Cancer Institute, University of California – San Diego, CA. (Invited Seminar). October 2018
17. "*Drosophila* model for glioblastoma reveals mechanisms of glial-cell specific mRNA regulation." Atlanta Neuroscience Symposium, Georgia State University, Atlanta, GA. (Invited Seminar). March 2019
* *this was a national seminar symposium held in Atlanta*
18. "A *Drosophila*-based Approach to Drug target Discovery for Human Glioblastoma." Bausch Healthcare. Virtual. (Invited Seminar). September 2019
19. "Drug target discovery and therapeutic opportunities for glioblastoma multiforme." Institute of Cancer Sciences. University of Glasgow. Virtual. (Invited Seminar). July 2020
20. "YAP/TAZ transcriptional co-activators create therapeutic vulnerability in EGFR mutant glioblastoma." O'Neal Comprehensive Cancer Center Research Seminar. University of Alabama at Birmingham. (Invited Seminar). March 2021
21. "YAP/TAZ transcriptional co-activators create therapeutic vulnerability in EGFR mutant glioblastoma." Department of Neurological Surgery. Northwestern University. (Invited Seminar). June 2021

b. Regional:

1. "Receptor Tyrosine Kinase Signaling Pathways in post-embryonic neurogenesis and pediatric brain tumors: from fruit fly models to drug targets for human clinical trials." Neuroscience Center, Georgia State University, Atlanta, GA. (Invited Seminar). October 2016
2. "Drug target discovery and therapeutic opportunities for glioblastoma multiforme." Molecular Biosciences Interdisciplinary Group. Kennesaw State University. (Invited Seminar). October 2020

c. Institutional:

1. "Manipulating the kinome in *Drosophila* Glia to Model Human Glioma." Department of Pharmacology, Emory University School of Medicine. (Invited Seminar). February 2011
2. "Manipulating the kinome in *Drosophila* Glia to Model Human Glioma." Department of Biology, Emory University. (Invited Seminar). February 2011
3. "An RNAi Screen in *Drosophila* glia reveals new kinases required for TORC2-Akt Signaling in human glioblastoma." Elkin Seminar, Winship Cancer Institute, Emory University School of Medicine. (Invited Seminar). November 2012
4. "A multidisciplinary approach to drug target discovery for glioblastoma." Grand Rounds, Department of Neurosurgery, Emory University School of Medicine. (Invited Seminar). June 2013
5. "An interdisciplinary approach to drug target discovery for glioblastoma." Cancer Cell

Biology Program Program, Winship Cancer Institute, Emory University School of Medicine. (Invited Seminar). November 2014

6. "Applying and Interviewing for Academic Jobs." Office of Postdoctoral Education. Emory University. (Invited Seminar and Discussion Panel). November 2014
7. "A multidisciplinary approach to drug target discovery for glioblastoma." Cancer Cell Biology Program, Winship Cancer Institute, Emory University School of Medicine. (Invited Seminar). February 2015
8. "Evaluation of the YAP Transcription Factor as a Novel Therapeutic Target in Pediatric High-grade Gliomas." Cancer Genetics and Epigenetics Program. Winship Cancer Institute, Emory University School of Medicine. (Invited Seminar). May 2016
9. "A multidisciplinary approach to drug target discovery for glioblastoma." Department of Biochemistry. Emory University School of Medicine. (Invited Seminar). September 2017
10. "Brain Tumor Disease-Specific and Scientific Resources." Omnix Site Visit, Phase I Unit, Winship Cancer Institute, Emory University School of Medicine. (Invited Oral Presentation and Round Table Discussion). March 2018
11. "Community Resiliency Model" Training Workshop. Emory University Hospital Midtown. Co-taught with Shimika Barolle from the Emory University School of Nursing. (Invited Seminar). June 2019
12. "Drug target discovery and therapeutic opportunities for glioblastoma multiforme." Biological Discoveries Through Chemical Innovation Initiative. Emory University. (Invited short Seminar). June 2020
13. "Community Resiliency Model: A Strengths-based Workshop to Promote Resiliency." Faculty Academic Advancement, Leadership, and Inclusion Lecture Series. Emory University School of Medicine. (Invited Seminar). September 2020

25. Invitations to National/International, Regional, and Institutional Conferences:

a. National and International:

1. "Modeling glioma in *Drosophila*." Ludwig Institute for Cancer Research Conference on the EGFR Signaling Cascade, San Diego, CA. (Invited Speaker). June 2006
** this was a national conference held in San Diego*
2. "Modeling human brain cancer in fruit flies." Cracking the Code with the Bear Symposium on Cancer Research. Northwestern University School of Medicine, Chicago, IL. (Invited Speaker). November 2006
3. "Manipulating *Drosophila* glia to model human glioma." AACR Special Conference on Genetics and Biology of Brain Cancers, San Diego, CA. (Invited Speaker). February 2009
4. "Modeling human brain cancer in *Drosophila*." Salk Institute Cell Cycle Meeting. The Salk Institute for Biological Studies, San Diego, CA. (Invited Speaker). July 2009
** this was a national conference held in San Diego*
5. "Manipulating *Drosophila* Glia and Glial Progenitor Cells to Model Human Brain Cancer." Mechanisms and Models of Cancer Symposium. The Salk Institute for Biological Studies, San Diego, CA. (Invited Speaker). August 2009
** this was a national conference held in San Diego*
6. "Manipulating *Drosophila* glia to model human brain cancer." Modelling Cancer In

- Drosophila*. Barcelona Biomed Conference, Institute for Research in Biomedicine, Barcelona, Spain. (Invited Plenary Speaker). September 2009
7. "Manipulating *Drosophila* Glia to Model Human Glioma." Cold Spring Harbor Meeting on Glia and Health and Disease. Cold Spring Harbor Laboratory, NY. Abstract (Invited Oral Presentation). July 2010
 8. "Manipulating *Drosophila* Glia to Model Human Brain Cancer." Meeting on Protein Phosphorylation and Cell Signaling. The Salk Institute for Biological Studies, San Diego, CA. (Invited Speaker). August 2010
* *this was a national conference held in San Diego*
 9. "Emerging trends in brain tumor research." American Brain Tumor Association, National Patient and Family Conference, American Brain Tumor Association, Chicago, IL. (Invited Speaker). July 2013
 10. "A multidisciplinary approach to drug target discovery for glioblastoma." American Brain Tumor Association Alumni Research Network Meeting, American Brain Tumor Association, Chicago, IL. (Invited Speaker). March 2013
 11. "A kinome-wide RNAi screen in *Drosophila* glia reveals new kinases that mediate cell proliferation and survival in human glioblastoma." 4th Quadrennial Meeting of the World Federation of Neuro-Oncology, Washington-D.C. Abstract (Invited Oral Presentation). November 2013
 12. "Funding brain tumor research: the R01 funding experience." American Brain Tumor Association Alumni Research Network Meeting, American Brain Tumor Association, Chicago, IL. (Invited Speaker and Panel Discussion). September 2014
 13. "A multidisciplinary approach to drug target discovery for glioblastoma." Barcelona Biomed Conference. *Drosophila* as a Model in Cancer, Barcelona Biomed Conference, Institute for Research in Biomedicine, Barcelona, Spain. (Invited Plenary Speaker). June 2015
 14. "Promotion and Tenure in the Basic Sciences at an R1 University." American Brain Tumor Association Alumni Research Network Meeting, American Brain Tumor Association, Chicago, IL. (Invited Speaker and Panel Discussion). September 2017
 15. "A multidisciplinary approach to drug target discovery for glioblastoma." Ian's Friend's Foundation WhatIFF Symposium, for pediatric brain tumor research, Atlanta, GA. (Invited Speaker). September 2017
* *this was a national conference held in Atlanta*
 16. "A *Drosophila* model for glioblastoma reveals mechanisms of tumor-cell specific mRNA regulation." Cold Spring Harbor Meeting on Glia and Health and Disease. Cold Spring Harbor Laboratory, NY. Abstract (Invited Oral Presentation). July 2018
 17. "Mentoring Scientific Trainees: The Emory Experience." American Brain Tumor Association Alumni Research Network Meeting, American Brain Tumor Association, Chicago, IL. (Invited Speaker and AARN Panel Discussion on Mentoring). September 2018
 18. "A multidisciplinary approach to drug target discovery for brain tumors." *Drosophila* as a Cancer Model, Barcelona Biomed Conference, Institute for Research in Biomedicine, Barcelona, Spain. Abstract (Invited Plenary Speaker). April 2019
 19. "A *Drosophila*-based Approach to Drug target Discovery for Human Glioblastoma." XIV European Meeting on Glial Cell Function in Health and Disease, Porto, Portugal. Abstract (Invited Symposium Speaker). July 2019
 20. "A multidisciplinary approach to drug target discovery for glioblastoma."

Ian's Friend's Foundation WhatIFF Symposium, for pediatric brain tumor research. Atlanta, GA. (Invited Speaker). September 2019
* this was a national conference held in Atlanta

21. "YAP/TAZ transcriptional co-activators create therapeutic vulnerability in EGFR mutant GBM." The Allied Genetics Conference. Virtual. Abstract (Invited Speaker). April 2020
22. "YAP/TAZ transcriptional co-activators create therapeutic vulnerability in EGFR mutant glioblastoma." 25th Annual Meeting of the Society for Neuro-Oncology. Virtual. Abstract (Invited Speaker). November 2020
23. "YAP/TAZ transcriptional co-activators create therapeutic vulnerability in EGFR mutant glioblastoma." Post-translational Regulation of Cell Signaling Meeting. Salk Institute for Biological Studies. Abstract (Invited Speaker). In person. June 2022

b. Regional:

1. "Evolutionarily conserved kinase pathways in glioblastoma." Southeastern Brain Tumor Research Meeting, University of Alabama at Birmingham, AL. Abstract (Invited Speaker). May 2019

c. Institutional:

1. "An interdisciplinary approach to drug target discovery for glioblastoma." Cancer Cell Biology Program Program Retreat. Winship Cancer Institute. Emory University School of Medicine. (Invited Speaker). October 2013
2. "A multidisciplinary approach to drug target discovery for glioblastoma." Winship Scientific Symposium. Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA. (Invited Speaker). February 2018
3. "YAP/TAZ transcriptional co-activators create therapeutic vulnerability in EGFR mutant glioblastoma." Cell and Molecular Biology Research Program Retreat, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA. (Invited Speaker). September 2020
4. "Translating YAP/TAZ Inhibition in GBM." Discovery and Developmental Therapeutics Research Program Virtual Retreat, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA. (Invited Speaker). October 2021

26. Abstract Presentations at National/International, Regional, and Institutional Conferences:

(only while in rank listed, *presenting author)

a. National and International:

1. **Read, R.D.***, T.S. Fenton, G. Gomez, J. Wykosky, S.R. Vandenberg, I. Babic, A. Iwanami, H. Yang, W.K. Cavenee, P.S. Mischel, F.B. Furnari, J.B. Thomas. A kinome-wide RNAi screen in *Drosophila* glia reveals new kinases that mediate cell proliferation and survival in human glioblastoma. Keystone Conference on PI 3- Kinase and Interplay with Other Signaling Pathways, Keystone, CO. Abstract (Poster). February 2013
2. **Read, R.D.***, T.S. Fenton, G. Gomez, J. Wykosky, S.R. Vandenberg, I. Babic, A. Iwanami, H. Yang, W.K. Cavenee, P.S. Mischel, F.B. Furnari, J.B. Thomas. A kinome-wide RNAi screen in *Drosophila* glia reveals new kinases that mediate cell proliferation and survival in human glioblastoma. 54th Annual *Drosophila* Research Conference, Washington, DC.

Abstract (Oral Presentation). November 2013

3. **Read, R.D.***, J. Marquez, C. Mosley. A kinome-wide RNAi screen in *Drosophila* glia and human GBM cells reveals that Stk17A drives neoplastic glial proliferation and invasion. 19th Annual Scientific Meeting of the Society for Neuro-Oncology, Miami, FL. Abstract (Oral Presentation). November 2014
4. **Read, R.D.*** Regulation of post-embryonic neurogenesis by the glial niche in the *Drosophila* brain. Cold Spring Harbor conference on Glia in Health and Disease, Cold Spring Harbor Laboratory, NY. Abstract (Poster). July 2014
5. **Read, R.D.***, C. Rowe. Morphogenesis and development of the postembryonic cortex glial niche. 56th Annual *Drosophila* Research Conference, Chicago, IL. Abstract (Oral Presentation). 2015
6. Brat, D.* , S Mukherjee, M. Chau, C. Zhang, C. Tucker-Burden, K. Moberg, J. Kong, R. Read, **R. Read**, C. Hadjipanayis. 2016. *Drosophila* Brat and human ortholog TRIM3 maintain stem cell equilibrium and suppress brain tumorigenesis by attenuating Notch signaling. 92nd Annual Meeting of the American-Association-of-Neuropathologists, Baltimore, MD. Abstract (Oral Presentation). May 2016
7. Wardwell-Ozgo, J.* , C. Mosley, H. Kornblum, **R. Read**. A kinome-wide RNAi screen in *Drosophila* glia and human GBM models reveals Stk17A drives neoplastic glial proliferation. The Allied Genetics Conference, Orlando, FL. Abstract (Oral Presentation). July 2016
8. Shah, N.N.* , **R. D. Read**, C. C. Rowe. A novel genetic screen in *Drosophila* designed to discover secreted factors that drive glioblastoma initiation and progression. The Allied Genetics Conference, Orlando, FL. Abstract (Poster). July 2016
9. Chen, A.S.* , **R.D. Read**. Understanding the mechanism of RIOK2 function in Glioblastoma. The Allied Genetics Conference, Orlando, FL. Abstract (Poster). July 2016
10. **Read, R.D.***, Z. Zhang, K. Vigneswaran, A. M. Kenney, J.J. Olson. A YAP/TAZ inhibitor for treatment of GBM: an interdisciplinary approach to drug target discovery for high-grade gliomas. American Brain Tumor Association 2016 Patient and Family Conference, Chicago, IL. Abstract (Poster). July 2016
11. Mukherjee, S.* , M. Chau, C. Tucker-Burden, C. Zhang, J. Kong, **R. Read**, D. Brat. 2016. Novel inhibitor of CDK5 signaling axis suppresses self-renewal properties of GBM stem cells and induces apoptosis. 21st Annual Meeting of the Society for Neuro-Oncology, Scottsdale, AZ. Abstract (Oral Presentation). November 2016
12. **Read, R.D.***, A. M. Kenney, M. Schniederjan, J.J. Olson. YAP function in pediatric glioblastomas. 21st Annual Meeting of the Society for Neuro-Oncology, Scottsdale, AZ. Abstract (Poster). November 2016
13. Vigneswaran, K.* , **R.D. Read**, J.J. Olson, T. MacDonald, S. Neill, M. Rossi. MET fusion, amplification, and/or overexpression defines diffusely invasive tumor cells in pediatric and adult glioblastoma. 21st Annual Meeting of the Society for Neuro-Oncology, Scottsdale, AZ. Abstract (Poster). November 2016
14. **Read, R.D.*** Reciprocal receptor tyrosine kinase signaling between neuroblasts and the glial niche is required for post-embryonic neurogenesis. Gordon Conference on Glial Biology: Functional Interactions Among Glia and Neurons, Ventura, CA. Abstract (Poster). March 2017
15. Vigneswaran, K.* , S-Y. Oh, Z. Zhang, J.J. Olson, **R. Read**. Characterizing the overexpression of Yki/YAP/TAZ transcription factors in gliomagenesis and a proposed novel treatment of glioblastomas. 22nd Annual Meeting of the Society for Neuro-Oncology,

San Francisco, CA. Abstract (Poster). November 2017

16. Oh. S.-Y.*, K. Vigneswaran, K., M. Schniederjan, C. Horbinski, D. Hambardzumyan, O. Becher, A.M. Kenney, **R. Read**. Therapeutic relevance of YAP/TAZ activity in pediatric high-grade glioma. 22nd Annual Meeting of the Society for Neuro-Oncology, San Francisco, CA. Abstract (Poster). November 2017
17. Chen, A. *, **R. Read**. Understanding the mechanism of RIOK2 function in glioblastoma. 22nd Annual Meeting of the Society for Neuro-Oncology, San Francisco, CA. Abstract (Poster). November 2017
18. Oh. S.-Y.*, K. Vigneswaran, K., M. Schniederjan, C. Horbinski, D. Hambardzumyan, O. Becher, A.M. Kenney, **R.D. Read**. Therapeutic relevance of YAP/TAZ activity in pediatric high-grade glioma. Cancer Stem Cell Conference. Case Comprehensive Cancer Center and National Center for Regenerative Medicine, Cleveland, OH. Abstract (Poster). August 2018
19. **Read, R.D.***, K. Vigneswaran, S. Lallani, S.-Y. Oh, Z. Zhang, J.J. Olson. A YAP/TAZ inhibitor for treatment of adult glioblastoma. Cancer Stem Cell Conference. Case Comprehensive Cancer Center National Center for Regenerative Medicine, Cleveland, OH. Abstract (Poster). August 2018
20. Vigneswaran, K.* , S.-Y. Oh, S. Lallani, **R. Read**, J. Olson. Characterizing the over-expression of Yki/YAP/TAZ transcription factors in gliomagenesis and results of a phase 0 clinical trial for a proposed novel treatment of glioblastomas. European Association of Neuro-Oncology (EANO) Annual Meeting, Stockholm, Sweden. Abstract (Oral Presentation). October 2018
21. Vigneswaran K.* , S.-Y. Oh, S. Lallani, **R. Read**, J. Olson. Targeting the Hippo Pathway and in EGFR amplified glioblastomas with Verteporfin and Results of Phase 0 Trial. American Academy of Neurological Surgery Annual Meeting, The Breakers, FL. Abstract (Oral Presentation). October 2018
22. Boyd, N.* , A. Chen, J. Marquez, **R. Read**. A requirement for RIOK2 catalytic activity in RTK-PI3K dependent glioblastoma. 23rd Annual Meeting of the Society for Neuro-Oncology, New Orleans, LA. Abstract (Poster). November 2018
23. Chen, A.* , **R.D. Read**. Understanding the mechanism of RIOK2 function in glioblastoma. 23rd Annual Meeting of the Society for Neuro-Oncology, New Orleans, LA. Abstract (Poster). November 2018
24. McSwain, L.* , S.-Y. Oh, K. Vigneswaran, S. Newman, T. MacDonald, **R. Read**. Met receptor tyrosine kinase fusions as oncogenic drivers in pediatric high grade glioma. 24th Neuro-Tumor Club Meeting, in association with The Society for Neuro- Oncology and the AACR Annual Meeting, Atlanta, GA. Abstract (Poster). April 2019
25. Chen, A.* , **R.D. Read**. Understanding the mechanism of RIOK2 function in glioblastoma. Southeastern Brain Tumor Research Meeting, University of Alabama at Birmingham, AL. Abstract (Poster). May 2019
26. **Read, R.D.***, K. Vigneswaran, N. Boyd, S. Lallani, S.-Y. Oh, A. Boucher, S. Neill, J.J. Olson. A *Drosophila*-based approach to drug target discovery for human glioblastomas. Cold Spring Harbor conference on Neurobiology of *Drosophila*. Cold Spring Harbor Laboratory, NY. Abstract (Poster). October 2019
27. Boyd, N.* , K. Vigneswaran, S. Lallani, S.-Y. Oh, A. Boucher, J.J. Olson, **R.D. Read**. Therapeutic Targeting of the YAP/TAZ Pathway in Glioblastoma with Verteporfin. American Association for Cancer Research Annual Meeting. Virtual. Abstract (Poster). June 2020

28. Oh, S-Y.*[^], **R.D. Read**. Therapeutic relevance of YAP/TAZ activity in pediatric high-grade glioma. Korea America Society in Biotech and Pharmaceuticals, KASBP Spring Symposium 2022. Abstract. (Invited Oral Presentation). June 2022
^ awarded KASBP Fellowship prize

b. Regional:

1. Vigneswaran K.*[^], S. Neill, C. Mosley, M. Rossi, J. Olson, **R. Read**. Utilization of patient derived neurospheres to study pathophysiology and treatment of glioblastoma. Annual Fall Georgia Neurological Society Winter Session, Oconee, GA. Abstract (Oral Presentation). December 2014
2. Vigneswaran K.*[^], S. Neill, C. Mosley, M. Rossi, J. Olson, **R. Read**. Characterizing the over-expression of Yki/YAP/TAZ transcription factors in gliomagenesis and a proposed novel treatment of glioblastomas. Southern Neurosurgical Society Annual Meeting. Abstract (Oral Presentation). February 2018
^ awarded the SNS Basic Science Award for top scoring basic research abstract from a resident or fellow
3. Lallani, S.*[^], K. Vigneswaran, S-Y. Oh, Z. Zhang, J.J. Olson, **R. Read**. Characterizing the overexpression of Yki/YAP/TAZ transcription factors in gliomagenesis and a proposed novel treatment of glioblastomas. 2018 Annual Spring Meeting Georgia Neurosurgical Society, Sea Island, GA. Abstract (Oral Presentation). May 2018
^ awarded the Spring Meeting Paper Award for top presentation from a student, resident, or fellow
4. Chen, A.*[^], **R.D. Read**. Understanding the mechanism of R1OK2 function in glioblastoma. 24th Neuro-Tumor Club Meeting, in association with The Society for Neuro-Oncology and the AACR Annual Meeting, Atlanta, GA. Abstract (Poster). April 2019
5. Boyd, N.*[^], **R.D. Read**. Therapeutic Targeting of the Hippo pathway in glioma. Southeastern Brain Tumor Research Meeting, University of Alabama at Birmingham, AL. Abstract (Invited Oral Presentation). May 2019
^ awarded the top presentation by resident or fellow

c. Institutional:

1. Vigneswaran, K.*[^], S. Neill S, C. Mosley C, M. Rossi M, J. Olson J, **R. Read**. Utilization of patient derived neurospheres to study pathophysiology and treatment of glioblastoma. Winship Scientific Research & Academic Development Symposium, Atlanta, GA. Abstract (Poster). October 2014
2. Obende, A.*[^], C. Rowe, C. Mosley, J. Wardwell-Ozgo, **R. Read**. Cell surface receptors and secreted proteins effects on glioblastoma. Undergraduate Independent Research Symposium, Emory University, Atlanta, GA. Abstract (Poster). April 2015
3. Shah, N.N.*[^], **R. D. Read**, C. C. Rowe. A novel genetic screen in *Drosophila* designed to discover secreted factors that drive glioblastoma initiation and progression. Summer Undergraduate Research Experience (SURE) program Research Symposium, Emory University, Atlanta, GA. Abstract (Poster). August 2016
4. Vigneswaran, K.*[^], S-Y. Oh, Z. Zhang, J.J. Olson, **R. Read**. Characterizing the overexpression of Yki/YAP/TAZ transcription factors in gliomagenesis and a proposed novel treatment of glioblastomas. Grady Memorial Medical Research Symposium, Atlanta, GA. Abstract (Oral Presentation). 2017
^ awarded the Resident Research Award for top presentation from a resident or fellow

5. Chen, A.* , **R.D. Read**. Understanding the mechanism of RIOK2 function in glioblastoma. 14th Annual GDBBS Division Student Advisory Council (DSAC) Student Research Symposium, Emory University, Atlanta, GA. Abstract (Poster). January 2017
6. Wright, D.* , J. Wardwell-Ozgo, **R. Read**. Annilin scaffolding protein is required for tumor cell-specific growth and survival in a *Drosophila* model of glioblastoma. Undergraduate Independent Research Symposium, Emory University, Atlanta, GA. Abstract (Poster). April 2017
7. Chen, A.* , **R.D. Read**. Understanding the mechanism of RIOK2 function in glioblastoma. 15th Annual GDBBS Division Student Advisory Council (DSAC) Student Research Symposium, Emory University, Atlanta, GA. Abstract (Poster). January 2018
8. Gulbranson, R.* , A. Chen, E.M. Miller, **R. Read**. Sexual differentiation of tumor volume in *Drosophila melanogaster* models of glioblastoma multiforme. Undergraduate Independent Research Symposium, Emory University, Atlanta, GA. Abstract (Poster). April 2019
9. Saborio, J.G.V.* , E. Young, R. Gulbranson, **R. Read**. Sex-based differences in innate immunity pathways in *Drosophila* glioblastoma model. Biology/NBB Undergraduate Research Symposium, Emory University, Atlanta, GA. Abstract (Poster). April 2022
10. Hsu, I.* , E. Young, **R. Read**. Investigating *Drosophila melanogaster* Glial Cell Morphology and Development using Gal4/UAS System. Undergraduate Research Symposium, Emory University, Atlanta, GA. Abstract (Poster). April 2022

27. Research Focus:

I am a trained developmental neurobiologist with a research focus on neuro-oncology. My research investigates the cellular origins and genetic and epigenetic basis of glioblastoma, using a combination of novel animal models and patient-derived tumor cell cultures and tissues, with the goal of developing new therapeutic strategies for these tumors.

28. Patents and Patent Applications:

Read, R.D. and J.B. Thomas. Non-mammalian animal models for glioma and use thereof. US Patent Application #61/146748, filed January 2009. (pending)

29. Grants Support:

a. Active Support:

i. Federally Funded Research Grants:

1. P.I., National Institutes of Health/National Institute of Neurological Disorders (NIH/NINDS), "Mechanisms of RIOK2 function in glioblastoma," R01NS100967, Total directs: \$1,015,655, 03/2017 - 08/2022 (NCE into 2023).
2. P.I., National Institutes of Health/National Institute of Neurological Disorders (NIH/NINDS), "MET kinase fusions in pediatric glioblastoma," R21NS116639-A1, Total directs: \$275,000, 12/2021 - 11/2023.
3. P.I., National Institutes of Health/National Institute of Neurological Disorders (NIH/NINDS), "MET kinase fusions in pediatric glioblastoma," R21NS116639-A1S1, Diversity Supplement for Julia Saborio, Total directs: \$35,000, 08/2022 - 07/2023. (pending, selected for award)

ii. Private Foundation Funded Research Grants:

1. P.I., Ben and Catherine Ivy Foundation, "A YAP/TAZ inhibitor for treatment of high grade gliomas," Emerging Leader Grant Award, Total directs: \$450,000, 07/2020 - 06/2022 (NCE).
2. P.I., CURE Foundation for Childhood Cancer, "Human Organoid Models of Pediatric High-Grade Gliomas," CURE Childhood Cancer Foundation Grant, Total directs: \$150,000, 07/2022 - 06/2023.

iii. Federally Funded Training Grant and Fellowship Mentorship:

1. Training Grant Mentor, (Corbett, Brown, Pls), National Institutes of Health/ National Institute of General Medical Sciences (NIH/NIGMS), "IRACDA Fellowships in Research and Science Training (FIRST)," K12GM000680, Total directs: \$5,690,670, 09/2020 - 08/2025. **I have no salary coverage/effort on this training grant.*

b. Previous Support:

i. Federally Funded Research Grants:

1. P.I., National Institutes of Health/National Institute of Neurological Disorders (NIH/NINDS), "Revealing new regulators of EGFR-PI3K driven glioma proliferation and migration," R00NS065974, Total directs: \$735,796, 07/2012 - 05/2015.

ii. Federally Funded Training Grant and Fellowship Mentorship:

1. Sponsor/Mentor for J. Wardwell-Ozgo, Mentee, (Eaton, PI), National Institutes of Health/ National Institute of General Medical Sciences, "IRACDA Fellowships in Research and Science Training (FIRST)," K12GM000680, Total directs: \$6,813,019, 09/2015 - 08/2016. **I had no salary coverage/effort on this training grant fellowship.*
2. Sponsor/Mentor for K. Vigneswaran, Mentee, (Oyesiku, Smith, Pls), National Institutes of Health/National Institute of Neurological Disorders (NIH/NINDS), "Mentoring Emory Neuroclinician Trainees in Research," R25NS06573 supplement, Total directs: \$125,936, 07/2016 - 06/2018. **I had no salary coverage/effort on this training grant fellowship.*
3. Sponsor/Mentor for N. Boyd, Mentee, (Levey, PI). National Institutes of Health/National Institute of Neurological Disorders (NIH/NINDS), Training in Translational Research in Neurology, T32NS007480, Total directs 2018-2020: \$790,092, 07/2018-06/2020. **I had no salary coverage/effort on this training grant fellowship.*

iii. Private Foundation Funded Research Grants:

1. P.I., Southeastern Brain Tumor Foundation, "Revealing a role for Stk17A in glioblastoma invasion and proliferation," SBTF Research Grant Award, Total directs: \$75,000, 05/2013 - 08/2014.
2. P.I., Rally Foundation for Childhood Cancer Research. "YAP inhibition in pediatric glioblastoma," Rally Foundation Grant, Total directs: \$150,000, 05/2015 - 06/2018.
3. P.I., American Brain Tumor Association, "A YAP/TAZ inhibitor for treatment of GBM," Discovery Award, Total directs: \$50,000, 07/2015 - 06/2017.

4. P.I., CURE Foundation for Childhood Cancer, "YAP/TAZ inhibition in pediatric high-grade gliomas," CURE Foundation for Childhood Cancer Grant, Total directs: \$100,000, 07/2016 - 06/2017.
5. Co-Investigator, (Hui-Kuo Shu, PI), CURE Childhood Cancer Foundation, "Id1 inhibition as a novel strategy for treatment of glioblastomas," CURE Foundation for Childhood Cancer Grant, Total directs: \$100,000, 07/2016 - 06/2017.

iv. Private Foundation Funded Training Grant and Fellowship Mentorship:

1. Sponsor/Mentor, (K. Vigneswaran, PI), Neurosurgery Research and Education Foundation, "Identification of small molecule inhibitors of novel receptor tyrosine kinase pathways in adult and pediatric glioblastoma," AANS/CNS Section on Neurological Surgery Research Fellowship Grant, Total directs: \$40,000, 07/2017 - 07/2018.
2. Sponsor/Mentor (S.-Y. Oh, PI), Rally Foundation for Childhood Cancer Research, "Therapeutic relevance of YAP/TAZ activity in pre-clinical pediatric HGG," Postdoctoral Fellowship, Total directs: \$100,000, 07/2018 - 06/2020.

v. Other:

1. P.I., Bayer Healthcare, "Testing the requirement for RIOK1 and RIOK2 kinase activity in glioblastoma," Grant4Targets Grant Award, Total directs: \$40,000, 07/2013 - 10/2014.
2. P.I., Emory University Research Committee, "Revealing a role for Stk17A in glioblastoma invasion and proliferation," Emory URC Grant, Total directs: \$30,000 05/2013 - 04/2014.
3. P.I., Winship Cancer Institute, "Identifying RIOK2 substrates in glioblastoma using a chemical genetics strategy," Billian Family Research Scholar-SunTrust Award, Total directs: \$50,000, 03/2014 - 02/2015.
4. P.I., Winship Cancer Institute, "Testing verteporfin treatment in glioblastoma," Winship Cancer Institute Pilot Award, Total directs: \$25,000, 03/2015 - 02/2016.
5. P.I., Winship Cancer Institute, "MET fusion, amplification, and/or overexpression defines diffusely invasive tumor cells in pediatric and adult glioblastoma," Winship Cancer Institute Pilot Award, Total directs: \$50,000, 07/2016 - 11/2017.
6. P.I., Emory University School of Medicine, "Targeting oncogenic MET fusions in pediatric high grade gliomas," Imagine, Innovate, and Impact Wow! Award, Total directs: \$50,000, 02/2019 – 01/2020.
7. P.I., Winship Cancer Institute, "Mechanisms of tumorigenesis and kinase inhibitor resistance in MET-mutant high-grade gliomas," Winship Cancer Institute Pilot Award, Total directs: \$50,000, 07/2021 - 06/2022.
8. P.I., Emory University School of Medicine, "Repurposing Verteporfin for treatment of Pediatric High-grade Gliomas," Morningside Center for Innovative and Affordable Medicine, Total directs: \$180,000, 07/2021 – 06/2023.
9. P.I., Emory University School of Medicine, "Drug Target Discovery with Human Organoid Models of Pediatric High-Grade Gliomas," Biological Discovery Through Chemical Innovation (BDCl) Accelerator Award, Total directs: \$40,000, 07/2022 – 06/2023.

30. Bibliography:

a. Published and in Press Research Articles (*corresponding/senior author):

1. Rogers, J.A., **R.D. Read**, J. Li, K.L. Peters, T.E. Smithgall. 1996. Autophosphorylation of the Fes tyrosine kinase: evidence for an intermolecular mechanism involving two kinase domain residues. *Journal of Biological Chemistry* 271: 17519-17525. PMID: 8663427.
2. **Read, R.D.**, J.M. Lionberger, T.E. Smithgall. 1997. Oligomerization of the Fes tyrosine kinase. *Journal of Biological Chemistry* 272:18498-18503. PMID: 9218495.
3. Miller, D T., **R. Read**, J. Rusconi, R.L. Cagan. 2000. The *Drosophila primo* locus encodes two low-molecular-weight tyrosine phosphatases. *Gene* 243: 1-9. PMID: 10675607.
4. **Read, R. D.**, E.A. Bach, R. L. Cagan. 2004. *Drosophila* C-terminal Src kinase negatively regulates organ growth and cell proliferation through inhibition of the Src, Jun N-terminal kinase, and STAT pathways. *Molecular and Cellular Biology* 24:6676-6689. PMID: 15254235. PMCID: PMC444864.
5. **Read, R.D.**, P.J. Goodfellow, E.R. Mardis, N. Novak, J.R. Armstrong, R.L. Cagan. 2005. A *Drosophila* model of Multiple Endocrine Neoplasia type 2. *Genetics* 171:1057-1081. PMID: 15965261. PMCID: PMC1456812.
6. Vidal, M., S. Warner, **R.D. Read**, R.L. Cagan. 2007. Differing Src signaling levels have distinct outcomes in *Drosophila*. *Cancer Research* 67:10278-10285. PMID: 17974969. PMCID: PMC2892182.
7. **Read, R.D.**, W.K. Cavenee, F.B. Furnari, J.B. Thomas. 2009. A *Drosophila* model for EGFR-Ras and PI3K dependent human glioma. *PLoS Genetics* 5(2):e1000374 PMCID: PMC2636203.
8. **Read, R.D.***, T.R. Fenton, G.G. Gomez, J. Wykosky, S.R. Vandenberg, I. Babic, H. Yang, A. Iwanami, P.S. Mischel, W.K. Cavenee, F.B. Furnari, J.B. Thomas. 2013. A kinome-wide RNAi screen in *Drosophila* glia reveals that the RIO kinases mediate cell proliferation and survival through TORC2-Akt signaling in glioblastoma. *PLoS Genetics* 9(2):e1003253. PMID:23459592. PMCID: PMC3573097.
9. Mukherjee, S.C. Tucker-Burden, C. Zhang, K. Moberg, **R. Read**, C. Hadjipanayis, D.J. Brat. 2016. *Drosophila* Brat and human ortholog TRIM3 maintain stem cell equilibrium and suppress brain tumorigenesis by attenuating Notch nuclear transport. *Cancer Research* 76(8):2443-2452. PMCID: PMC4873416.
10. Mukherjee, S.C. Tucker-Burden, E. Kaissi, A. Newsam, M. Chau, C. Zhang, B. Diwedi, M. Rupji, S. Seby, J. Kowalski, J. Kong, **R.D. Read**, D. J. Brat. 2018. CDK5 inhibition resolves PKA/cAMP-independent CREB1 phosphorylation in glioma stem cells. *Cell Reports* 23(6):1651-1664. PMID:29742423. PMCID: PMC5987254.
11. **Read, R.D.*** 2018. The Pvr receptor tyrosine kinase signaling promotes post-embryonic morphogenesis and survival of glia and neural progenitor cells in *Drosophila*. *Development*. 145(23). doi 10.1242/dev/164285. PMID: 30327326.
12. Chen, A.S., J. Wardwell-Ozgo, N.N. Shah, D. Wright, C.L. Appin, K. Vigneswaran, D.J. Brat, H.I. Kornblum, **R.D. Read.*** 2018. Drak/Stk17A drives neoplastic glial proliferation through modulation of MRLC signaling. *Cancer Research*. doi: 10.1158/0008-5472.CAN-18-0482. PMID: 30530503.
13. Robinson, M.H., V. Maximov, S. Lallani, H. Farooq, M.D. Taylor, **R.D. Read**, A.M. Kenney. 2019. Upregulation of the chromatin remodeler HELLS is mediated by YAP1 in Sonic Hedgehog Medulloblastoma. *Science Reports*. 2019 Sep 20;9(1):13611. doi: 10.1038/s41598-019-50088-1. PMID: 31541170.
14. Chen, Z., C.J. Herting, J.L. Ross, B. Gabanic, M.P. Vallcorba, F. Szulzewsky, M.L. Wojciechowicz, P.J. Cimino, R. Ezhilarasan, E.P. Sulman, M. Ying, A. Ma'ayan, **R.D. Read**,

- D. Hambardzumyan. 2020. Genetic driver mutations introduced in identical cell-of-origin in murine glioblastoma reveal distinct immune landscapes but similar response to checkpoint blockade. *Glia*. 2020 Jul 8. doi: 10.1002/glia.23883. PMID: 32639068.
15. Vigneswaran, K., N.H. Boyd, S.-Y. Oh, S. Lallani, A. Boucher, S.G. Neill, J.J. Olson, **R.D. Read**.* 2020. YAP/TAZ transcription factors create therapeutic vulnerability to verteporfin in EGFR mutant glioblastoma. *Clinical Cancer Research*. Nov 10;clincanres.0018.2020. doi: 10.1158/1078-0432.CCR-20-0018. PMID: 33172899.
 16. Ross, J.L., Z. Chen, C.J. Herting, F. Szulzewsky, M.P. Vallcorba, L. Monterroza, J. Switchenko, P.J. Cimino, A. Mackay, C. Jones, **R.D. Read**, T. MacDonald, M. Schniederjan, O.J. Becher, D. Hambardzumyan. 2020. PDGFB is a Potent Inflammatory Driver in Pediatric High-Grade Glioma. *Brain*. Dec 10;awaa382 doi: 10.1093/brain/awaa382. PMID: 33300045.
 17. Saborio, J.G., E.E. Young, A.S. Chen, **R.D. Read**. A protocol to use *Drosophila melanogaster* larvae to model human glioblastoma. 2022. *Star Protocols*. in press.

b. Manuscripts Submitted and/or in Revision (*corresponding/senior author):

1. Chen, A.S., S.-Y. Oh, N.H. Boyd, J. Marquez, E. Young, R. Gulbranson, J.W.L. Allen, J.A.G. Hamilton, E. R. Legan, **R.D. Read**.* RIOK2 maintains EGFR and TORC2 signaling and oncogene expression in glioblastoma through the RNA-binding protein IMP3. in revision for *Glia*, released on Bioarchives: doi: <https://doi.org/10.1101/2020.12.07.413385>.
**significantly delayed by covid-19 shutdown.
2. Chen, A.S., R. Gulbranson, E. Legan, J. Marquez, **R.D. Read**.* A chemical genetic approach indicates that RIOK2 upregulates Myc to drive glial neoplasia. in revision for *Disease Models and Mechanisms*. **significantly delayed by covid-19 shutdown.

c. Manuscripts in Preparation (*corresponding/senior author):

1. Oh, S.-Y., D. Hambardzumyan, M.J. Schniederjan, C. Horbinski, A.M. Kenney, **R.D. Read**,* The YAP transcription factor drives tumor stem cell identity in pediatric high-grade gliomas. in preparation for *Neuro-Oncology*.
2. Oh, S.-Y., S. Newman, L. McSwain, K. Vigneswaran, S. Neil, T. MacDonald, **R. D. Read**,* MET fusions in diffusely invasive pediatric glioblastoma. in preparation for *Neuro-Oncology*.

d. Review Articles (*corresponding/senior author):

1. **Read, R.D.*** 2011. *Drosophila melanogaster* as a model system for human brain cancers. *Glia*.10.1002/glia.21148 epub. **invited
2. Koehler, A., A. Karve, J. Arbiser, D. Plas, X. Qi, **R.D. Read**, A. Sasaki, D. Bhattacharya, L. Kallay, G. Vaibhavjumar, D.P. Krummel, S. Sengupta. Repurposing Drugs in GBMs, from Bench to Bedside. *Pharmaceuticals* special issue on "Malignant Glioma: Novel Therapeutic Strategies." in press. **invited
3. **R.D. Read**** 2022. Repurposing the drug verteporfin as anti-neoplastic therapy for glioblastoma. *Neuro Oncol*. Jan 31;noac019. doi: 10.1093/neuonc/noac019.
**invited

e. Book Chapters (*corresponding/senior author):

1. Chen, A. and **R.D. Read**.* 2019. *Drosophila* models for human brain cancers. Book chapter

for “*Drosophila Models in Cancer.*” Springer Nature., edited by W.M. Deng. Springer International Publishing. pp 207-224. DOI: 10.1007/978-3-030-23629-8_12. PMID: 31520357. ****invited**

f. Published Abstracts (*corresponding/senior author):

1. **Read, R.D.***, T.S. Fenton, G. Gomez, J. Wykosky, S.R. Vandenberg, I. Babic, A. Iwanami, H. Yang, W.K. Cavenee, P.S. Mischel, F.B. Furnari, and J.B. Thomas. 2013. A kinome-wide RNAi screen in *Drosophila* glia reveals new kinases that mediate cell proliferation and survival in human glioblastoma. *Neuro-Oncology*, Vol. 15, pp. 12.
2. **Read, R.D.***, J. Marquez, and C. Mosley. 2014. A kinome-wide RNAi screen in *Drosophila* glia and human GBM cells reveals that Stk17A drives neoplastic glial proliferation and invasion. *Neuro-Oncology*, Vol. 16, pp. 57.
3. Brat, D., S Mukherjee, M. Chau, C. Zhang, C. Tucker-Burden, K. Moberg, J. Kong, R. Read, **R. Read**, C. Hadjipanayis. 2016. *Drosophila* Brat and human ortholog TRIM3 maintain stem cell equilibrium and suppress brain tumorigenesis by attenuating Notch signaling. *Journal of Neuropathology and Experimental Neurology*, Vol. 75, pp. 570.
4. Vigneswaran, K., **R.D. Read**, J.J. Olson, T. MacDonald, S. Neill, M. Rossi. 2016. MET fusion, amplification, and/or overexpression defines diffusely invasive tumor cells in pediatric and adult glioblastoma. *Neuro-Oncology*, Vol. 18, pp. 46.
5. Mukherjee, S., M. Chau, C. Tucker-Burden, C. Zhang, J. Kong, **R. Read**, D. Brat. 2016. Novel inhibitor of CDK5 signaling axis suppresses self-renewal properties of GBM stem cells and induces apoptosis. *Neuro-Oncology*, Vol. 18, pp. 187.
6. **Read, R.D.***, A. M. Kenney, M. Schniederjan, and J.J. Olson. 2016. YAP function in pediatric glioblastomas. *Neuro-Oncology*, Vol. 18, pp. 155.
7. **Read, R.D.***, S.-Y. Oh, M. Schniederjan, A. M. Kenney, O. Becher, J.J. Olson. 2017. YAP/TAZ function in pediatric glioblastomas. *Neuro-Oncology*, Vol. 19, pp. 50-51.
8. Vigneswaran K, S.-Y. Oh, Z. Zhang, J. Olson, and **R. Read**. 2017. Characterizing the over-expression of Yki/YAP/TAZ transcription factors in gliomagenesis and a proposed novel treatment of glioblastoma. *Neuro-Oncology*, Vol. 19, pp. 56.
9. Chen, A. **R. Read**. 2017. Understanding the mechanism of RIOK2 function in glioblastoma. *Neuro-Oncology*, Vol. 19, pp. 53.
10. Oh, S.-Y., K. Vigneswaran, M.J. Schniederjan, C. Horbinski, D. Hambardzumyan, O. Becher, A.M. Kenney, and **Read, R.** 2017. Therapeutic relevance of YAP/TAZ activity in pediatric high grade glioma. *Neuro-Oncology*, Vol. 19, pp. 197.
11. Vigneswaran, K.*, S.-Y. Oh, S. Lallani, **R. Read**, J. Olson. 2018. Characterizing the over-expression of Yki/YAP/TAZ transcription factors in gliomagenesis and results of a phase 0 clinical trial for a proposed novel treatment of glioblastomas. *Neuro-Oncology*, Vol. 20, pp. 218.
12. Boyd, N., A. Chen, J. Marquez, and **R. Read**. 2018. A requirement for RIOK2 catalytic activity in RTK-PI3K dependent glioblastoma. *Neuro-Oncology*, Vol. 20, pp. 43.
13. Chen, A. **R. Read**. 2018. Understanding the mechanism of RIOK2 function in glioblastoma. *Neuro-Oncology*, Vol. 20, pp. 45.
14. **Read, R.D.** 2019. A *Drosophila*-based approach to drug target discovery for human glioblastomas. *Glia* Vol. 67, pp. E16.

30. Contributions Not Otherwise Noted:

a. Clinical Trials and IRB protocols

1. Co-Investigator, (Olson, PI), IRB00045732, Core for Brain Tumor, Cerebrospinal Fluid and Plasma Samples, 2012 – current.
Responsibilities: This protocol allows for the collection and research use of de-identified surgical tissue specimens from brain tumor patients at Emory. My lab and I collect and process tissues for research purposes to create patient-derived cell cultures, xenografts, and annotated tissue microarrays.
Impact: The research resources that my team and I have created from these patient tissues have formed the basis of several research projects, grants, and publications in my laboratory, and have been shared with several other research groups on campus for use in their research grants and publications.
2. Co-Investigator, (Olson, PI), IRB00082472, Winship2986-15, A Phase 0 study of Visudyne (liposomal verteporfin) in patients undergoing surgery for high grade glioma. 2015 - 2018.
Responsibilities: I designed the project, obtained funding through competitive grants from external foundations (American Brain Tumor Association, Rally Foundation), administered funding, supervised clinical trainees in preparation of the IRB and IACUC protocols and processing of patient tissues for research, and prepared the manuscript for publication on which I am the senior and corresponding author. Dr. Olson recruited participants from his clinical practice, performed surgeries, oversaw patient care, collected research specimens for research processing, and reported to the IRB.
Impact: : This project resulted in a new investigator-initiated phase 1/2 clinical trial of Visudyne for glioblastoma patients here at Emory. I presented the data from this phase 0 trial to Bausch Health leadership and to the Ivy Foundation, and secured their support of a proposed phase 1/2 clinical trial of liposomal verteporfin (Visudyne) in glioblastoma patients now being opened at Winship's Phase I Unit.
3. Co-Investigator, (W. Read, PI), STUDY00000974, Winship5070-20, A Phase1/2 study of Visudyne (liposomal verteporfin) in persons with recurrent high grade EGFR-mutated Glioblastoma, 2020 – current.
Responsibilities: I designed the project, obtained funding through competitive grants from external foundations (Ivy Foundation), administer funding, supervise research and clinical mentees, and will prepare progress reports and manuscripts for publication. This project is a collaboration with Dr. William Read, Dr. Jeff Olson, and Dr. Donald Harvey, who will manage clinical patient care and clinical regulatory duties. I will perform and oversee all correlative and translational studies performed using patient tissues and patient genetic and pathological diagnostic information.
Impact: This project is in a new investigator-initiated phase 1/2 clinical trial of Visudyne for glioblastoma patients. The Ivy Foundation awarded \$500,000 of funding to support this project, Bausch agreed to donate >\$6,000,000 of drug for this project, and the FDA and IRB regulatory paperwork for the phase 1/2 has been approved and the trial is now open through the Phase I Unit of the Winship Cancer Institute. We will enroll 25-30 patients.
4. Clinical Study Participant, NCT04431414, A Study of Immune Responses to the Virus That Causes COVID-19 (CoVPN 5001), Hope Clinic of Emory Vaccine Center, Emory University, 11/2020 - 2/2021.

b. Contracts in support of Clinical Trails

1. Co-Investigator, (W. Read, PI), Bausch Health, "A Phase 1 / 2 study of Visudyne (liposomal verteporfin) in persons with recurrent high grade EGFR-mutated glioblastoma."
Impact: This contract, in which Bausch has agreed to donate up to 4,113 vials of

15 mg Visudyne (commercial value >\$6,000,000) based on my research presentation to their leadership team, which supports IRB STUDY00000974, our phase 1/2 clinical trial of liposomal verteporfin (Visudyne).